Literature DB >> 31585625

NK/T-cell lymphomas.

Eric Tse1, Yok-Lam Kwong2.   

Abstract

NK/T-cell lymphomas are extranodal EBV-related malignancies, mostly of NK-cell and occasionally of T-cell lineage. They are divided into nasal, non-nasal, and disseminated subtypes. Nasal NK/T-cell lymphomas involve the nose, nasopharynx and the upper aerodigestive tract. Non-nasal NK/T-cell lymphomas involve the skin, gastrointestinal tract, testis and other sites. Disseminated NK/T-cell lymphoma involves multiple organs, and may present with a leukemic phase. Initial evaluation requires positron emission tomography computed tomography (PET/CT) and quantification of circulating EBV DNA. Radiotherapy alone is inadequate with frequent relapses. Anthracycline-containing regimens are ineffective. Regimens incorporating asparaginase are currently the standard. For stage I/II disease, combined chemotherapy and radiotherapy is recommended. For stage III/IV disease, asparaginase-containing regimens are needed. Autologous hematopoietic stem cell transplantation (HSCT) is of limited efficacy, whereas allogeneic HSCT may be useful in patients with stage III/IV and relapsed diseases. Immunotherapy with antibodies against CD30, programmed cell death protein 1 and CD38 is promising.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asparaginase; EBV; Immunotherapy; NK/T-cell lymphoma; Nasal; Non-nasal; PD1; PET/CT

Mesh:

Substances:

Year:  2019        PMID: 31585625     DOI: 10.1016/j.beha.2019.06.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  12 in total

1.  Dynamic evaluation of the prognostic value of 18F-FDG PET/CT in extranodal NK/T-cell lymphoma, nasal type.

Authors:  Pengpeng Xu; Rui Guo; Jianhua You; Shu Cheng; Jian Li; Huijuan Zhong; Chenwei Sun; Haoping Xu; Hengye Huang; Biao Li; Weili Zhao
Journal:  Ann Hematol       Date:  2021-02-26       Impact factor: 3.673

2.  Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime.

Authors:  Canjing Zhang; Huiwen Xu; Xianxian Sui; Lina Chen; Bobin Chen; Haozhen Lv; Songmei Wang; Xuanyi Wang
Journal:  Mol Ther Oncolytics       Date:  2022-05-04       Impact factor: 6.311

Review 3.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Oropharynx and Nasopharynx.

Authors:  Cécile Badoual
Journal:  Head Neck Pathol       Date:  2022-03-21

4.  Survival trends for extranodal NK/T-cell lymphoma, nasal type from different anatomical sites: a population-based study.

Authors:  Lu He; Yixin Zou; Xiaolu Tang; Jia Wang; Lingxiao Xing; Jing Zhang; Jianyong Li; Jingjing Guo; Yi Miao
Journal:  Ann Transl Med       Date:  2021-05

Review 5.  Extranodal NK/T cell lymphoma.

Authors:  Seong Hyun Jeong
Journal:  Blood Res       Date:  2020-07-31

6.  The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection.

Authors:  Xia Lu; Ang Wei; Xu Yang; Jun Liu; Siqi Li; Ying Kan; Wei Wang; Tianyou Wang; Rui Zhang; Jigang Yang
Journal:  Front Med (Lausanne)       Date:  2022-01-21

7.  Intestinal NK/T cell lymphoma: A case report.

Authors:  Hui Li; Wen Lyu
Journal:  World J Gastroenterol       Date:  2020-07-21       Impact factor: 5.742

8.  [Clinical characteristics and survival analysis of primary intestinal extranodal NK/T-cell lymphoma, nasal type].

Authors:  Y Li; X J Wang; Y N Li; X H Wang; Y Q Shi; M Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14

9.  Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma.

Authors:  Changqian Bao; Lixia Zhu; Wenbin Qian; Xiujin Ye
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

10.  Primary pulmonary extranodal NK/T-cell lymphoma: a case report and literature review.

Authors:  Yanli Wang; Zhengxia Wang; Chaojie Wu; Xinyun Zhao; Ningfei Ji; Mao Huang
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.